Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch

Pipeline Candidates Use Same Platform

The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.

Nasdaq
Vaccitech is looking to join the biotech IPO boom, and is aiming to raise $100m with its NASDAQ debut.

The UK biotech company which co-developed the ChadOx1 vaccine platform used in the Oxford/AstraZenecavaccine is preparing to launch a $100m initial public offering in the US.

The company looks likely to raise that sum when it makes its debut on the NASDAQ exchange in the coming...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip